Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS

Abstract Autoimmune disorders of the central nervous system (CNS) comprise a broad spectrum of clinical entities. The stratification of patients based on the recognized autoantigen is of great importance for therapy optimization and for concepts of pathogenicity, but for most of these patients, the...

Full description

Bibliographic Details
Main Authors: Ramona Gerhards, Lena Kristina Pfeffer, Jessica Lorenz, Laura Starost, Luise Nowack, Franziska S. Thaler, Miriam Schlüter, Heike Rübsamen, Caterina Macrini, Stephan Winklmeier, Simone Mader, Mattias Bronge, Hans Grönlund, Regina Feederle, Hung-En Hsia, Stefan F. Lichtenthaler, Juliane Merl-Pham, Stefanie M. Hauck, Tanja Kuhlmann, Isabel J. Bauer, Eduardo Beltran, Lisa Ann Gerdes, Aleksandra Mezydlo, Amit Bar-Or, Brenda Banwell, Mohsen Khademi, Tomas Olsson, Reinhard Hohlfeld, Hans Lassmann, Tania Kümpfel, Naoto Kawakami, Edgar Meinl
Format: Article
Language:English
Published: BMC 2020-11-01
Series:Acta Neuropathologica Communications
Subjects:
Online Access:https://doi.org/10.1186/s40478-020-01086-2
id doaj-48e9a477e7444c7f8deb69565051b888
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Ramona Gerhards
Lena Kristina Pfeffer
Jessica Lorenz
Laura Starost
Luise Nowack
Franziska S. Thaler
Miriam Schlüter
Heike Rübsamen
Caterina Macrini
Stephan Winklmeier
Simone Mader
Mattias Bronge
Hans Grönlund
Regina Feederle
Hung-En Hsia
Stefan F. Lichtenthaler
Juliane Merl-Pham
Stefanie M. Hauck
Tanja Kuhlmann
Isabel J. Bauer
Eduardo Beltran
Lisa Ann Gerdes
Aleksandra Mezydlo
Amit Bar-Or
Brenda Banwell
Mohsen Khademi
Tomas Olsson
Reinhard Hohlfeld
Hans Lassmann
Tania Kümpfel
Naoto Kawakami
Edgar Meinl
spellingShingle Ramona Gerhards
Lena Kristina Pfeffer
Jessica Lorenz
Laura Starost
Luise Nowack
Franziska S. Thaler
Miriam Schlüter
Heike Rübsamen
Caterina Macrini
Stephan Winklmeier
Simone Mader
Mattias Bronge
Hans Grönlund
Regina Feederle
Hung-En Hsia
Stefan F. Lichtenthaler
Juliane Merl-Pham
Stefanie M. Hauck
Tanja Kuhlmann
Isabel J. Bauer
Eduardo Beltran
Lisa Ann Gerdes
Aleksandra Mezydlo
Amit Bar-Or
Brenda Banwell
Mohsen Khademi
Tomas Olsson
Reinhard Hohlfeld
Hans Lassmann
Tania Kümpfel
Naoto Kawakami
Edgar Meinl
Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS
Acta Neuropathologica Communications
Autoantigen
Multiple sclerosis
Neuroinflammation
Autoimmunity
author_facet Ramona Gerhards
Lena Kristina Pfeffer
Jessica Lorenz
Laura Starost
Luise Nowack
Franziska S. Thaler
Miriam Schlüter
Heike Rübsamen
Caterina Macrini
Stephan Winklmeier
Simone Mader
Mattias Bronge
Hans Grönlund
Regina Feederle
Hung-En Hsia
Stefan F. Lichtenthaler
Juliane Merl-Pham
Stefanie M. Hauck
Tanja Kuhlmann
Isabel J. Bauer
Eduardo Beltran
Lisa Ann Gerdes
Aleksandra Mezydlo
Amit Bar-Or
Brenda Banwell
Mohsen Khademi
Tomas Olsson
Reinhard Hohlfeld
Hans Lassmann
Tania Kümpfel
Naoto Kawakami
Edgar Meinl
author_sort Ramona Gerhards
title Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS
title_short Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS
title_full Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS
title_fullStr Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS
title_full_unstemmed Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS
title_sort oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the cns
publisher BMC
series Acta Neuropathologica Communications
issn 2051-5960
publishDate 2020-11-01
description Abstract Autoimmune disorders of the central nervous system (CNS) comprise a broad spectrum of clinical entities. The stratification of patients based on the recognized autoantigen is of great importance for therapy optimization and for concepts of pathogenicity, but for most of these patients, the actual target of their autoimmune response is unknown. Here we investigated oligodendrocyte myelin glycoprotein (OMGP) as autoimmune target, because OMGP is expressed specifically in the CNS and there on oligodendrocytes and neurons. Using a stringent cell-based assay, we detected autoantibodies to OMGP in serum of 8/352 patients with multiple sclerosis, 1/28 children with acute disseminated encephalomyelitis and unexpectedly, also in one patient with psychosis, but in none of 114 healthy controls. Since OMGP is GPI-anchored, we validated its recognition also in GPI-anchored form. The autoantibodies to OMGP were largely IgG1 with a contribution of IgG4, indicating cognate T cell help. We found high levels of soluble OMGP in human spinal fluid, presumably due to shedding of the GPI-linked OMGP. Analyzing the pathogenic relevance of autoimmunity to OMGP in an animal model, we found that OMGP-specific T cells induce a novel type of experimental autoimmune encephalomyelitis dominated by meningitis above the cortical convexities. This unusual localization may be directed by intrathecal uptake and presentation of OMGP by meningeal phagocytes. Together, OMGP-directed autoimmunity provides a new element of heterogeneity, helping to improve the stratification of patients for diagnostic and therapeutic purposes.
topic Autoantigen
Multiple sclerosis
Neuroinflammation
Autoimmunity
url https://doi.org/10.1186/s40478-020-01086-2
work_keys_str_mv AT ramonagerhards oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT lenakristinapfeffer oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT jessicalorenz oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT laurastarost oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT luisenowack oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT franziskasthaler oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT miriamschluter oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT heikerubsamen oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT caterinamacrini oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT stephanwinklmeier oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT simonemader oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT mattiasbronge oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT hansgronlund oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT reginafeederle oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT hungenhsia oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT stefanflichtenthaler oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT julianemerlpham oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT stefaniemhauck oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT tanjakuhlmann oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT isabeljbauer oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT eduardobeltran oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT lisaanngerdes oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT aleksandramezydlo oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT amitbaror oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT brendabanwell oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT mohsenkhademi oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT tomasolsson oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT reinhardhohlfeld oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT hanslassmann oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT taniakumpfel oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT naotokawakami oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
AT edgarmeinl oligodendrocytemyelinglycoproteinasanoveltargetforpathogenicautoimmunityinthecns
_version_ 1724398724530044928
spelling doaj-48e9a477e7444c7f8deb69565051b8882020-12-06T12:32:39ZengBMCActa Neuropathologica Communications2051-59602020-11-018111710.1186/s40478-020-01086-2Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNSRamona Gerhards0Lena Kristina Pfeffer1Jessica Lorenz2Laura Starost3Luise Nowack4Franziska S. Thaler5Miriam Schlüter6Heike Rübsamen7Caterina Macrini8Stephan Winklmeier9Simone Mader10Mattias Bronge11Hans Grönlund12Regina Feederle13Hung-En Hsia14Stefan F. Lichtenthaler15Juliane Merl-Pham16Stefanie M. Hauck17Tanja Kuhlmann18Isabel J. Bauer19Eduardo Beltran20Lisa Ann Gerdes21Aleksandra Mezydlo22Amit Bar-Or23Brenda Banwell24Mohsen Khademi25Tomas Olsson26Reinhard Hohlfeld27Hans Lassmann28Tania Kümpfel29Naoto Kawakami30Edgar Meinl31Institute of Clinical Neuroimmunology, Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität MünchenInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität MünchenInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität MünchenInstitute of Neuropathology, University Hospital MünsterInstitute of Neuropathology, University Hospital MünsterInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität MünchenInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität MünchenInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität MünchenInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität MünchenInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität MünchenInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität MünchenTherapeutic Immune Design, Department of Clinical Neuroscience, Karolinska InstitutetTherapeutic Immune Design, Department of Clinical Neuroscience, Karolinska InstitutetInstitute for Diabetes and Obesity, Monoclonal Antibody Core Facility, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH)Neuroproteomics, School of Medicine, Klinikum rechts der Isar, German Center for Neurodegenerative Diseases (DZNE), Technical University of MunichNeuroproteomics, School of Medicine, Klinikum rechts der Isar, German Center for Neurodegenerative Diseases (DZNE), Technical University of MunichResearch Unit Protein Science, Helmholtz Center MunichResearch Unit Protein Science, Helmholtz Center MunichInstitute of Neuropathology, University Hospital MünsterInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität MünchenInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität MünchenInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität MünchenInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität MünchenDepartment of Neurology, University of PennsylvaniaChildren’s Hospital of PhiladelphiaNeuroimmunology Unit, Department of Clinical Neuroscience, Karolinska InstitutetNeuroimmunology Unit, Department of Clinical Neuroscience, Karolinska InstitutetInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität MünchenCenter for Brain Research, Medical UniversityInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität MünchenInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität MünchenInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospitals, Ludwig-Maximilians-Universität MünchenAbstract Autoimmune disorders of the central nervous system (CNS) comprise a broad spectrum of clinical entities. The stratification of patients based on the recognized autoantigen is of great importance for therapy optimization and for concepts of pathogenicity, but for most of these patients, the actual target of their autoimmune response is unknown. Here we investigated oligodendrocyte myelin glycoprotein (OMGP) as autoimmune target, because OMGP is expressed specifically in the CNS and there on oligodendrocytes and neurons. Using a stringent cell-based assay, we detected autoantibodies to OMGP in serum of 8/352 patients with multiple sclerosis, 1/28 children with acute disseminated encephalomyelitis and unexpectedly, also in one patient with psychosis, but in none of 114 healthy controls. Since OMGP is GPI-anchored, we validated its recognition also in GPI-anchored form. The autoantibodies to OMGP were largely IgG1 with a contribution of IgG4, indicating cognate T cell help. We found high levels of soluble OMGP in human spinal fluid, presumably due to shedding of the GPI-linked OMGP. Analyzing the pathogenic relevance of autoimmunity to OMGP in an animal model, we found that OMGP-specific T cells induce a novel type of experimental autoimmune encephalomyelitis dominated by meningitis above the cortical convexities. This unusual localization may be directed by intrathecal uptake and presentation of OMGP by meningeal phagocytes. Together, OMGP-directed autoimmunity provides a new element of heterogeneity, helping to improve the stratification of patients for diagnostic and therapeutic purposes.https://doi.org/10.1186/s40478-020-01086-2AutoantigenMultiple sclerosisNeuroinflammationAutoimmunity